Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
D-Cycloserine (DCS), a broad-spectrum antibiotic and NMDA receptor modulator, exhibits immunomodulatory effects beyond its known neurological and antimicrobial functions. This study investigated DCS's therapeutic potential in inflammatory bowel disease (IBD) and colitis-associated colorectal cancer (CAC) using in vitro and in vivo models. In lipopolysaccharide (LPS)-stimulated NCM460 cells, DCS inhibited NLRP3 inflammasome activation and restored tight junction protein expression. In dextran sulfate sodium (DSS)-induced murine colitis, both preventive and therapeutic DCS regimens attenuated inflammation, reduced histopathological damage, and preserved intestinal barrier integrity. In azoxymethane (AOM)/DSS-induced CAC, DCS decreased tumor burden and reduced Ki-67+ cell proliferation without systemic toxicity. These findings position DCS as a promising dual-target candidate for IBD and CAC management through NLRP3-caspase-1-GSDMD pathway inhibition and epithelial barrier maintenance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.intimp.2025.115209 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
KLK1 as an Epithelial-Specific Brake Inhibits Colorectal Tumorigenesis by Suppressing B1R-Mediated Fibroblast Phenotypic Transition.
Adv Sci (Weinh)
August 2025
State Key Laboratory of Pharmaceutical Biotechnology and Nanjing Drum Tower Hospital, School of Life Sciences, Chemistry and Biomedicine Innovation Center, Nanjing University, 163 Xianlin Avenue, Nanjing, Jiangsu, 210023, P. R. China.
Inflammatory bowel disease (IBD) is increasing worldwide, and the persistence of chronic inflammation may lead to colitis-associated colorectal cancer (CAC). KLK1 expression is reduced in colitis, and its potential role in the intestinal mucosal barrier is still unclear. Here, KLK1 is investigated whether a supplement can reduce colitis and colorectal carcinogenesis.
View Article and Find Full Text PDFTherapeutic effects of D-cycloserine in mouse models of IBD and CAC: Targeting NLRP3 inflammasome and intestinal barrier integrity.
Int Immunopharmacol
July 2025
College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China. Electronic address:
D-Cycloserine (DCS), a broad-spectrum antibiotic and NMDA receptor modulator, exhibits immunomodulatory effects beyond its known neurological and antimicrobial functions. This study investigated DCS's therapeutic potential in inflammatory bowel disease (IBD) and colitis-associated colorectal cancer (CAC) using in vitro and in vivo models. In lipopolysaccharide (LPS)-stimulated NCM460 cells, DCS inhibited NLRP3 inflammasome activation and restored tight junction protein expression.
View Article and Find Full Text PDFSusceptibility to inflammatory bowel diseases promotes invasive carcinomas in a murine model of ATF6-driven colon cancer.
J Crohns Colitis
July 2025
Chair of Nutrition and Immunology, School of Life Sciences, Technical University of Munich, Freising-Weihenstephan, Germany.
Background And Aims: Chronic inflammation in inflammatory bowel disease (IBD) patients represents a risk factor for developing colitis-associated cancer (CAC). We previously linked the endoplasmic reticulum unfolded protein response (UPRER) signal transducer activating transcription factor 6 (ATF6) with spontaneous microbiota-dependent colonic adenoma development in mice expressing epithelial-specific activated ATF6 (nATF6IEC).
Methods: To investigate IBD-related risk factors in ATF6-mediated tumorigenesis, we crossed tumor-free monoallelic (tg/wt) nATF6IEC mice with interleukin-10 deficient mice (Il10-/-).
Inflammatory Bowel Disease Induces Colorectal Cancer: Risk Factors, Triggering Mechanisms, and Treatment With Phyto-Derivatives.
Phytother Res
August 2025
College of Food and Bioengineering, Xihua University, Chengdu, China.
Colorectal cancer (CRC), one of the most prevalent malignant neoplasms, ranks as a leading cause of cancer-related mortality on a global scale. A particularly aggressive variant of CRC is colitis-associated colon cancer (CAC). Patients with chronic inflammatory bowel disease (IBD) are at increased risk for CAC.
View Article and Find Full Text PDFThe Roles of Dietary Bioactive Compounds in Alleviating Inflammatory Bowel Disease-Associated Colorectal Cancer.
Food Sci Nutr
June 2025
State Key Laboratory of Cardiovascular Diseases, Shanghai East Hospital, School of Medicine Tongji University Shanghai China.
Inflammatory bowel disease (IBD)-associated colorectal cancer (CRC) is a serious global health issue. Owing to the successful mimicking of the entire process of CRC induced by IBD, azoxymethane (AOM) and dextran sulfate sodium (DSS)-induced colitis-associated cancer (CAC) animal models have been widely used to study the carcinogenic mechanisms of IBD-associated CRC and aid in the discovery of new candidate target drugs for CRC treatment. This article summarizes the molecular characteristics and mechanisms of the AOM/DSS-induced CAC animal model and reports the effects and mechanisms of dietary active ingredients such as phenolics, flavonoids, terpenes, polysaccharides, alkaloids, and other food extracts in the prevention and treatment of AOM/DSS-induced CAC in preclinical trials.
View Article and Find Full Text PDF